Changes in Weight and Metabolic Indices after Switching to Aripiprazole Once-Monthly in Patients with Schizophrenia According to Prior Oral Antipsychotics.

IF 2.3 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Seoyoung Kim, Kyu Young Lee, Hyun Seung Chee, Joonho Choi, Young-Hoon Kim, Won-Hyoung Kim, Heon-Jeong Lee, Ji-Woon Jeong, Yu Sang Lee, Il Ho Park, Jong Woo Kim, Hong Seok Oh, Moon-Doo Kim, Euitae Kim, Jun Soo Kwon
{"title":"Changes in Weight and Metabolic Indices after Switching to Aripiprazole Once-Monthly in Patients with Schizophrenia According to Prior Oral Antipsychotics.","authors":"Seoyoung Kim, Kyu Young Lee, Hyun Seung Chee, Joonho Choi, Young-Hoon Kim, Won-Hyoung Kim, Heon-Jeong Lee, Ji-Woon Jeong, Yu Sang Lee, Il Ho Park, Jong Woo Kim, Hong Seok Oh, Moon-Doo Kim, Euitae Kim, Jun Soo Kwon","doi":"10.1055/a-2959-4334","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Antipsychotic-induced weight gain and metabolic disturbance are common in schizophrenia, but liability varies across agents. Aripiprazole has a relatively favorable metabolic profile, yet evidence on aripiprazole once-monthly, its long-acting injectable formulation, remains limited. We hypothesized that switching from a higher liability antipsychotic would yield a greater weight reduction than switching from a lower liability agent.</p><p><strong>Methods: </strong>This 16-week, prospective, open-label, multicenter study enrolled patients with stable schizophrenia. Participants were stratified by the metabolic liability of their prior oral antipsychotic (high vs. low). Participants received aripiprazole once-monthly 400 mg intramuscularly every 4 weeks, with cross-titration of the prior agent. Anthropometric and metabolic parameters were assessed every 4 weeks from baseline. Weight changes at week 16 were the principal outcome, and all analyses were exploratory. Mixed models for repeated measures evaluated changes over time, adjusting for covariates.</p><p><strong>Results: </strong>Among the 151 participants (100 low-risk and 51 high-risk participants), weight, body mass index, and waist circumference decreased significantly in the high-risk group only, and more high-risk patients reached clinically meaningful improvement. Most lipid and glycemic indices changed little, although low-density lipoprotein cholesterol and total cholesterol decreased in both groups. Psychiatric symptoms remained stable. In a subgroup switched from oral aripiprazole (<i>n</i>=73), anthropometric and metabolic parameters were all unchanged.</p><p><strong>Discussion: </strong>In patients previously exposed to high-metabolic-risk antipsychotics, switching to aripiprazole once-monthly was associated with short-term reductions in weight and central adiposity-consistent with the reversal of the prior agents' metabolic burden-while psychiatric stability was maintained. Longer-term studies are needed to confirm their durability and clinical significance.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacopsychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2959-4334","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Antipsychotic-induced weight gain and metabolic disturbance are common in schizophrenia, but liability varies across agents. Aripiprazole has a relatively favorable metabolic profile, yet evidence on aripiprazole once-monthly, its long-acting injectable formulation, remains limited. We hypothesized that switching from a higher liability antipsychotic would yield a greater weight reduction than switching from a lower liability agent.

Methods: This 16-week, prospective, open-label, multicenter study enrolled patients with stable schizophrenia. Participants were stratified by the metabolic liability of their prior oral antipsychotic (high vs. low). Participants received aripiprazole once-monthly 400 mg intramuscularly every 4 weeks, with cross-titration of the prior agent. Anthropometric and metabolic parameters were assessed every 4 weeks from baseline. Weight changes at week 16 were the principal outcome, and all analyses were exploratory. Mixed models for repeated measures evaluated changes over time, adjusting for covariates.

Results: Among the 151 participants (100 low-risk and 51 high-risk participants), weight, body mass index, and waist circumference decreased significantly in the high-risk group only, and more high-risk patients reached clinically meaningful improvement. Most lipid and glycemic indices changed little, although low-density lipoprotein cholesterol and total cholesterol decreased in both groups. Psychiatric symptoms remained stable. In a subgroup switched from oral aripiprazole (n=73), anthropometric and metabolic parameters were all unchanged.

Discussion: In patients previously exposed to high-metabolic-risk antipsychotics, switching to aripiprazole once-monthly was associated with short-term reductions in weight and central adiposity-consistent with the reversal of the prior agents' metabolic burden-while psychiatric stability was maintained. Longer-term studies are needed to confirm their durability and clinical significance.

根据既往口服抗精神病药物,精神分裂症患者每月一次改用阿立哌唑后体重和代谢指标的变化
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmacopsychiatry
Pharmacopsychiatry 医学-精神病学
CiteScore
7.10
自引率
9.30%
发文量
54
审稿时长
6-12 weeks
期刊介绍: Covering advances in the fi eld of psychotropic drugs, Pharmaco psychiatry provides psychiatrists, neuroscientists and clinicians with key clinical insights and describes new avenues of research and treatment. The pharmacological and neurobiological bases of psychiatric disorders are discussed by presenting clinical and experimental research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书